Panagiotis Argyropaidas

Panagiotis Argyropaidas

Auto-generated profile, based on publicly available information

Panagiotis Argyropaidas

Institute of Computer Science, Foundation for Research and Technology-Hellas (FORTH), Heraklion, Greece

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in The Breast Journal
Verified
Journal Article
Open access
PPPaula Poikonen-Saksela
Paula Poikonen-Saksela
EKEvangelos Karademas
Evangelos Karademas
LVLeena Vehmanen
Leena Vehmanen
MUMeri Utriainen
Meri Utriainen
Haridimos KondylakisHaridimos Kondylakis
Haridimos Kondylakis
JMJohanna Mattson
Johanna Mattson
Background. Despite excellent prognosis of early breast cancer, the patients face problems related to decreased quality of life and mental health. There is a need for easily available interventions targeting modifiable factors related to these problems. The aim of this study was to test the use of a new digital supportive intervention platform for early breast cancer patients. Material and Methods. Ninety‐seven early breast cancer patients answered questions on wellbeing, exercise, and sociodemographic factors before systemic adjuvant treatment at the Helsinki University Hospital. Based on these answers and predictive algorithms for anxiety and depression, they were guided onto one or several digital intervention paths. Patients under 56 years of age were guided onto a nutrition path, those who exercised less than the current guideline recommendations onto an exercise path, and those at risk of mental health deterioration onto an empowerment path. Information on compliance was collected at 3 months on the amount of exercise and quality of life using EORTC‐C30 scale, anxiety and depression using HADS scale at baseline and 12 months, and log‐in information at 3 and 12 months. Results. Thirty‐two patients followed the empowerment path, 43 the nutrition path, and 75 the exercise path. On a scale of 1–5, most of the participants (mean = 3.4; SD 0.815) found the interventions helpful and would have recommended testing and supportive interventions to their peers (mean = 3.70; SD 0.961). During the 10‐week intervention period, the mean number of log‐ins to the empowerment path was 3.69 (SD = 4.24); the nutrition path, 4.32 (SD = 2.891); and the exercise path, 8.33 (SD = 6.293). The higher number of log‐ins to the empowerment (rho = 0.531, P = 0.008, and n = 24) and exercise paths (rho = 0.330, P = 0.01, and n = 59) was related to better global quality of life at one year. The number of log‐ins correlated to the weekly amount of exercise in the exercise path (cc 0.740, P value <0.001, and n = 20). Conclusion. Patients’ attitudes towards the interventions were positive, but they used them far less than was recommended. A randomized trial would be needed to test the effect of interventions on patients’ QoL and mental health.

25 August 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
MVMaria Vasilopoulou
Maria Vasilopoulou
DKDimitrios Kyrou
Dimitrios Kyrou
GKGeorgios Karakatsoulis
Georgios Karakatsoulis
PAPanagiotis Argyropaidas
Panagiotis Argyropaidas
LSLydia Scarfò
Lydia Scarfò
PURPOSE: The MyPal study (ClinicalTrials.gov identifier: NCT04370457 ) is a randomized controlled clinical trial assessing an eHealth intervention on the quality of life (QoL) of patients with chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). METHODS: Patients who were receiving or had previously received treatment for CLL or MDS were randomly assigned (1:1) to access the MyPal digital health platform versus standard of care. The MyPal platform included a smartphone application used to report QoL status and symptoms via standardized questionnaires or spontaneous reporting. The primary end point was QoL at 12 months, assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 General Questionnaire and the EuroQol EQ-5D-3L. Secondary end points included physical and emotional functioning, measured by the Integrated Palliative Care Outcome Scale (IPOS) scale, satisfaction with care, measured by the EORTC PATSAT-C33, and overall survival (OS). Additionally, the Edmonton Symptom Assessment System (ESAS), Brief Pain Inventory (BPI), and Emotion Thermometers (ET) QoL questionnaires were assessed only in the intervention group. RESULTS: A total of 171 patients (97 and 74 in the control and intervention arms, respectively) who answered multiple questionnaires were analyzed. The intervention group reported a significant decrease in pain (β 2 = –0.48 [–0.77 to –0.19], P < .001) compared with the control group (β 1 = 0.3 [0.09 to 0.5], P = .01). Communication and pain measured by IPOS reduced equally in both groups (β 2 = 0 [–0.03 to 0.02], P = .82; β 2 = –0.01 [–0.02 to 0], P = .1, respectively). Family involvement significantly increased over time only for the intervention group. The other items of EORTC QLQ-C30, EuroQol EQ-5D-3L, IPOS, and PATSAT-C33 remained unchanged in both groups. The intervention group displayed a significant improvement in all ESAS, BPI, and ET scales. OS was similar in both groups. CONCLUSION: The MyPal intervention improved several QoL aspects and led to a statistically significant decrease in pain compared with the control group.